Neo Ivy Capital Management’s Emergent Biosolutions EBS Stock Holding History

Neo Ivy Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-514	Closed	-$22K	–	459
2022 Q1	$22K	Buy	+514	New	+$22.7K	0.02%	423
2021 Q4	–	Sell	-117	Closed	-$9K	–	479
2021 Q3	$9K	Buy	+117	New	+$7.08K	0.01%	417
2021 Q1	–	Sell	-403	Closed	-$36K	–	508
2020 Q4	$36K	Buy	403 +342	+561%	+$31.4K	0.04%	332
2020 Q3	$6K	Sell	61 -56	-48%	-$6.04K	0.01%	435
2020 Q2	$9K	Sell	117 -442	-79%	-$32.9K	0.01%	417
2020 Q1	$32K	Buy	+559	New	+$32.2K	0.05%	348
2019 Q2	–	Sell	-10,683	Closed	-$539K	–	306
2019 Q1	$539K	Buy	10,683 +4,048	+61%	+$239K	0.31%	147
2018 Q4	$393K	Buy	+6,635	New	+$428K	0.31%	144

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Neo Ivy Capital Management's EBS Position: Q2 2022 in Review

Neo Ivy Capital Management sold out of Emergent Biosolutions (EBS) in Q2 2022, closing a stake of 514 shares — an estimated $22K sold.

Neo Ivy Capital Management first reported a position in EBS in Q4 2018 and held it in 8 quarters. The position peaked at $539K in Q1 2019. 232 funds tracked by Wall St. Rank hold EBS as of Q2 2022.

Neo Ivy Capital Management reported no remaining Emergent Biosolutions position as of Q2 2022 after selling out during the quarter.
Neo Ivy Capital Management sold 514 Emergent Biosolutions shares in Q2 2022, an estimated $22K.
Neo Ivy Capital Management first reported a position in Emergent Biosolutions in Q4 2018 and held it in 8 quarters.
Neo Ivy Capital Management's Emergent Biosolutions position peaked at $539K in Q1 2019.
232 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2022.

Based on Neo Ivy Capital Management's 13F filing for Q2 2022, filed 16 Aug 2022.